NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00309478,Randomized Study Comparing CMF and Goserelin + Tamoxifen in Premenopausal Receptor-positive Patients,https://clinicaltrials.gov/study/NCT00309478,,COMPLETED,"Primarily, this clinical investigation compared the efficacy of cyclophosphamide + methotrexate + fluorouracil chemotherapy vs. goserelin + tamoxifen treatment in terms of prognosis (disease-free survival, overall survival) in premenopausal patients with potentially curative, operated hormone receptor-positive breast cancer.",NO,Early-stage Breast Cancer,DRUG: Cyclophosphamide|DRUG: Methotrexate|DRUG: Fluorouracil implant|DRUG: Goserelin|DRUG: Tamoxifen,Disease-free survival|Overall survival,Toxicities,,Austrian Breast & Colorectal Cancer Study Group,AstraZeneca,FEMALE,"ADULT, OLDER_ADULT",PHASE3,1099,NETWORK,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,ABCSG-5,1990-12,2004-06,2004-06,2006-04-03,,2023-06-29,,
